Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial

Patients with mantle cell lymphoma (MCL) generally respond to first‐line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL‐001 study in relapsed...

Descripción completa

Detalles Bibliográficos
Autores principales: Goy, Andre, Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029780/
https://www.ncbi.nlm.nih.gov/pubmed/25921098
http://dx.doi.org/10.1111/bjh.13456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029780/
https://www.ncbi.nlm.nih.gov/pubmed/25921098
http://dx.doi.org/10.1111/bjh.13456

Ejemplares similares